
On 23 April 2026, the Serbian Parliament adopted the Law on Trading Practices for Certain Types of Products (ʺLawʺ), which shall enter into force on 1 May 2026.

The Serbian Commission for Protection of Competition (CPC) has denied Roche and ADOC's request to extend their exclusive distribution agreement exemption, marking a significant shift in regulatory oversight. This July 2024 decision affects the distribution of three crucial pharmaceuticals: Kadcyla, Perjeta, and Tecentriq.
